StrideBio Announces Closing of $81.5M Series B Financing
Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million.
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
Belgium, March 16th, 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million. The financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.
Syndesi Therapeutics announces positive results from two additional Phase I studies of its novel SV2A modulator SDI-118, providing strong support for the initiation of further clinical trials in cognitive impairment
27 Jan 2021 — Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces results from two Phase I studies of its lead compound SDI-118.
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNATargeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
14 Dec 2020 — Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced a $100 million Series B financing.
Walden seeking to develop breakthrough medicines to reverse kidney disease progression.
06 Oct 2020 — Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today announced its launch with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures.
ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19
28 Jul 2020 — ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices.